PDCD1 and non-small cell lung carcinoma: For instance, it was shown that patients with NSCLC treated with prednisone at the time of anti-PD-1/PD-L1 immunotherapy (alone or in combination with CTLA4 blockade) have worse outcomes than control patients [78].